A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study consists of a Screening Period (Day - 21 to Day -1), a Treatment Period during which visits will occur every 2 weeks, an End of Treatment visit within 14 days of the decision to discontinue treatment for any reason, and a Safety Follow-up visit at 30 days after the last dose of study treat...
The study consists of a Screening Period (Day - 21 to Day -1), a Treatment Period during which visits will occur every 2 weeks, an End of Treatment visit within 14 days of the decision to discontinue treatment for any reason, and a Safety Follow-up visit at 30 days after the last dose of study treatment. PRL3-zumab will be administered by intravenous (IV) infusion till patient meets any of the discontinuation criteria (progressive disease, clinically or per RECIST v1.1, intolerable toxicity or withdrawal of consent). One cycle of treatment will be 4 weeks (2 infusions, 2-weeks ±2 days apart).
Tracking Information
- NCT #
- NCT04452955
- Collaborators
- Parexel
- Investigators
- Not Provided
Get Well Soon